Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. China
  4. Shanghai Stock Exchange
  5. Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
  6. News
  7. Summary
    600196   CNE000000X38

SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.

(600196)
  Report
End-of-day quote Shanghai Stock Exchange  -  2022-09-27
29.56 CNY   -2.92%
09/13China Approves Drug Registration Application for Fosun Pharmaceutical's Anti-Schizophrenia Medication
MT
09/08Neovii and Fosun Pharma Enter into an Exclusive Agreement
AQ
09/08Shandong Liancheng Precision Manufacturing Co., Ltd entered into an agreement to acquire 3.9858% stake in Shanghai Shen-li High Tech Co., Ltd. from Shanghai Fosun Pharmaceutical Co., Ltd. and Shanghai Fulian Technology Co., Ltd. for CNY 61 million.
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Shanghai Fosun Pharmaceutical : Stada lifts forecasts after telling suitors to raise bids

03/17/2017 | 06:48am EDT
Logo of the pharmaceutical company Stada Arzneimittel AG is pictured at its headquarters in Bad Vilbel

FRANKFURT (Reuters) - German drugmaker Stada (>> STADA Arzneimittel AG), at the centre of a takeover battle between two private equity consortia, has raised its medium-term forecasts, pressing for a higher valuation after telling suitors their 4.7 billion euro (4.04 billion pounds) bids were too low.

FRANKFURT (Reuters) - German drugmaker Stada (>> STADA Arzneimittel AG), at the centre of a takeover battle between two private equity consortia, has raised its medium-term forecasts, pressing for a higher valuation after telling suitors their 4.7 billion euro (4.04 billion pounds) bids were too low.

Anticipating growth in its core generics business and additional cost savings the company now expects adjusted earnings before interest tax, depreciation and amortisation (EBITDA) to come in at between 570 million euros and 590 million in 2019.

Previously the company had said it expected adjusted EBITDA to reach about 510 million euros by then.

The takeover battle for Stada pits a combination of Advent and Permira against Bain and Cinven. Both have now made takeover offers at 58 euros per share, valuing the company at 4.7 billion euros including debt, according to people familiar with the matter.

However, Stada abruptly postponed the bidding process on Thursday evening to give the rival suitors a chance to improve their offers.

It denied reports that it wanted give a potential third consortium comprising a buyout group and a strategic investor time to enter the process.

Reuters has also reported that China's Shanghai Fosun Pharmaceutical (>> Shanghai Fosun Pharmaceutical (Group)) is looking into entering the bidding tussle, potentially siding with an investor such as CVC.

Stada shares traded 0.6 percent lower at 56.5 euros by 1135 GMT and analysts warned of a risk of the bidding fizzling out.

"Stada is playing a risky game in our view... In a worst case scenario, even as it is unlikely in our view, the bidders could withdraw from the bidding process," brokerage Warburg said in a research note.

Increasing bids further without tying up with a strategic investor, who would be able to realise potential synergies, is seen as challenging for the buyout groups, analysts said.

"The indicative offers, which are said to amount to 58 euros plus dividend, are likely to already widely reflect the increased targets. Therefore, we would not expect the bids to be increased substantially," said Thomas Maul, analyst at DZ Bank.

Stada also said that it expects 2019 adjusted group sales of between 2.65 billion euros and 2.7 billion, up from a previous outlook of about 2.6 billion euros, and adjusted net income at between 250 million euros and 270 million.

($1 = 0.9284 euros)

(Reporting by Arno Schuetze and Harro ten Wolde; Editing by Keith Weir)


© Reuters 2017
Stocks mentioned in the article
ChangeLast1st jan.
SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD. -2.92% 29.56 End-of-day quote.-39.60%
STADA ARZNEIMITTEL 0.00%End-of-day quote.-8.87%
All news about SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
09/13China Approves Drug Registration Application for Fosun Pharmaceutical's Anti-Schizophre..
MT
09/08Neovii and Fosun Pharma Enter into an Exclusive Agreement
AQ
09/08Shandong Liancheng Precision Manufacturing Co., Ltd entered into an agreement to acquir..
CI
09/06Executive Directors, Senior Management to Acquire More Shares in Shanghai Fosun Pharmac..
MT
09/06Fosun Tourism Group's Shares Fall After Report That Parent Company Is Reducing Stake
DJ
09/04Fosun Pharma Shares Slide After Controlling Shareholder Plans Stake Sale
DJ
08/30Fosun Pharma to Invest $145 Million on New Vaccine Headquarters
MT
08/29Shanghai Fosun Pharma Posts 37% Profit Drop in H1; Revenue Beats Forecast
MT
08/29Shanghai Fosun Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ende..
CI
08/29Shanghai Fosun Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ende..
CI
More news
Financials
Sales 2022 45 085 M 6 282 M 6 282 M
Net income 2022 4 086 M 569 M 569 M
Net Debt 2022 15 069 M 2 100 M 2 100 M
P/E ratio 2022 16,2x
Yield 2022 1,71%
Capitalization 71 874 M 10 015 M 10 015 M
EV / Sales 2022 1,93x
EV / Sales 2023 1,68x
Nbr of Employees 36 604
Free-Float 60,8%
Chart SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
Duration : Period :
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Last Close Price 29,56 CNY
Average target price 46,74 CNY
Spread / Average Target 58,1%
EPS Revisions
Managers and Directors
Yu Qing Chen Co-Chief Executive Officer
De Yong Wen Co-Chief Executive Officer & Executive Director
Dong Ming Li Co-President
Shirley Wu General Manager-Finance Management Department
Yi Fang Wu Co-Chairman